XOMA Royalty Corp
XOMA
View Detailed Chart
36.430USD
-2.340-6.04%
Close 10/10, 16:00（ET）Quotes delayed by 15 min
439.44MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.04%
5 Days
-7.87%
1 Month
-0.90%
6 Months
+80.44%
Year to Date
+38.62%
1 Year
+33.39%
View Detailed Chart
TradingKey Stock Score of XOMA Royalty Corp
Currency: USD Updated: 2025-10-09Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XOMA Royalty Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
69.667
Target Price
+91.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
XOMA Royalty Corp Highlights
StrengthsRisks
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 372.66% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.49M.
Undervalued
The company’s latest PE is -27.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.23M shares, increasing 6.51% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 719.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
XOMA Royalty Corp Info
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
Ticker SymbolXOMA
CompanyXOMA Royalty Corp
CEOMr. Owen P. Hughes, Jr.
Websitehttps://www.xoma.com/
Related Instruments
+0.20%
-0.06%
+0.31%
-5.27%
0.00%
0.00%
-1.45%
-0.30%
-0.23%
-2.69%
-2.10%
-1.17%
-0.86%
-3.70%
-2.15%
-5.01%
+0.44%
0.00%
-5.48%
0.00%Popular Symbols
